Simultaneous assessment of short‐term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: An instrumental variable analysis
- 30 October 2006
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 54 (11) , 3390-3398
Abstract
Objective To simultaneously assess the short‐term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis. Methods A population of 49,711 Medicare beneficiaries ages 65 years and older who initiated nonselective NSAID or selective cyclooxygenase 2 inhibitor therapy between January 1, 1999, and December 31, 2002, was identified. The increase in risk of GI complications and MI within 180 days after initiation of NSAID (rofecoxib, diclofenac, ibuprofen, and naproxen compared with celecoxib) therapy was assessed using instrumental variable analysis. Results Compared with nonselective NSAIDs, celecoxib reduced the risk of GI complications by 1.4 per 100 users but increased the risk of MI by 0.3 per 100 users. Rofecoxib decreased GI complications by 1.1 per 100 users and increased the risk of MI by 0.3 per 100 users. Using celecoxib as the reference exposure showed an increase in the MI risk for rofecoxib (risk difference [RD] 1.40, 95% confidence interval [95% CI] −0.20, 3.01) and diclofenac (RD 6.07, 95% CI −0.02, 12.15). The RD for naproxen as well as its upper 95% CI was the lowest of all NSAIDs (RD −0.30, 95% CI −2.74, 2.14) and there was no significant difference in GI complication rates among all NSAIDs. Conclusion In this instrumental variable analysis, diclofenac and rofecoxib had the least favorable benefit–risk balance among NSAIDs in older adults.Keywords
This publication has 39 references indexed in Scilit:
- Instrumental Variable Analysis of Secondary Pharmacoepidemiologic DataEpidemiology, 2006
- Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental VariableEpidemiology, 2006
- Long-term study proposed for COX2 inhibitorsNature Reviews Drug Discovery, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital recordsAmerican Heart Journal, 2004
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983